Rodman & Renshaw weighs in on Curis (CRIS +4.7%) following its unveiling of an agreement...
Rodman & Renshaw weighs in on Curis (CRIS +4.7%) following its unveiling of an agreement with the Leukemia & Lymphoma Society. Analysts with the firm say that funding from the organization will support the development of CUDC-907, as well as add value to early stage pipeline.
From other sites
at CNBC.com (Mar 31, 2014)
at CNBC.com (Nov 6, 2013)
at CNBC.com (Jul 29, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs